Suppr超能文献

三种非氟喹诺酮类药物对代表性细菌分离株的体外活性。

In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.

作者信息

Barry A L, Fuchs P C, Brown S D

机构信息

The Clinical Microbiology Institute, Wilsonville, Oregon 97070, USA.

出版信息

Antimicrob Agents Chemother. 2001 Jun;45(6):1923-7. doi: 10.1128/AAC.45.6.1923-1927.2001.

Abstract

In vitro susceptibility tests were performed to document the inhibitory activities of three nonfluorinated quinolone (NFQ) compounds (PGE 9262932, PGE 9509924, and PGE 4175997) compared to those of ciprofloxacin, levofloxacin, and trovafloxacin against 3,030 bacterial isolates. The spectra of the NFQ agents included most gram-positive species as well as quinolone-susceptible Enterobacteriaceae. Ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus strains were inhibited by the NFQ series at < or =1.0 microg/ml. The NFQ compounds were not very active against Pseudomonas aeruginosa and most other nonfermentative gram-negative bacilli. Against other species, the potency of the NFQ agents was similar to that of trovafloxacin. Continued investigation of the NFQ compounds seems to be warranted.

摘要

进行了体外药敏试验,以记录三种非氟喹诺酮(NFQ)化合物(PGE 9262932、PGE 9509924和PGE 4175997)与环丙沙星、左氧氟沙星和曲伐沙星相比,对3030株细菌分离株的抑制活性。NFQ药物的抗菌谱包括大多数革兰氏阳性菌以及对喹诺酮敏感的肠杆菌科细菌。耐环丙沙星、耐甲氧西林金黄色葡萄球菌菌株在浓度≤1.0微克/毫升时被NFQ系列抑制。NFQ化合物对铜绿假单胞菌和大多数其他非发酵革兰氏阴性杆菌活性不强。对于其他菌种,NFQ药物的效力与曲伐沙星相似。似乎有必要继续对NFQ化合物进行研究。

相似文献

1
In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
Antimicrob Agents Chemother. 2001 Jun;45(6):1923-7. doi: 10.1128/AAC.45.6.1923-1927.2001.
4
[In vitro evaluation of lomefloxacin].
Arzneimittelforschung. 1989 Aug;39(8):832-5.
5
In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
Antimicrob Agents Chemother. 2004 Jul;48(7):2771-7. doi: 10.1128/AAC.48.7.2771-2777.2004.

引用本文的文献

2
Safety of oral nemonoxacin: A systematic review of clinical trials and postmarketing surveillance.
Front Pharmacol. 2022 Dec 9;13:1067686. doi: 10.3389/fphar.2022.1067686. eCollection 2022.
3
Activities of Nemonoxacin and Other Antimicrobial Agents Against Human and Isolates and Their Defined Resistance Mechanisms.
Front Microbiol. 2019 Aug 13;10:1890. doi: 10.3389/fmicb.2019.01890. eCollection 2019.
4
In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.
Microb Drug Resist. 2016 Oct;22(7):578-584. doi: 10.1089/mdr.2016.0021. Epub 2016 Jun 7.
6
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
Antimicrob Agents Chemother. 2009 Nov;53(11):4915-20. doi: 10.1128/AAC.00078-09. Epub 2009 Sep 8.
8
Prevalence and characterization of invasive isolates of Streptococcus pyogenes with reduced susceptibility to fluoroquinolones.
Antimicrob Agents Chemother. 2005 May;49(5):2130-2. doi: 10.1128/AAC.49.5.2130-2132.2005.

本文引用的文献

1
New uses for new and old quinolones and the challenge of resistance.
Clin Infect Dis. 2000 Feb;30(2):243-54. doi: 10.1086/313677.
2
Fluoroquinolone toxicity profiles: a review focusing on newer agents.
Clin Infect Dis. 1999 Feb;28(2):352-64. doi: 10.1086/515104.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验